

January 29, 2018

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS
--	---

Dear Sirs,

Sub: **Unaudited Financial Results for the Quarter and Nine months
Period ended December 31, 2017**


Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Unaudited Financial Results of the Company for the Quarter and Nine months period ended December 31, 2017 as approved by the Board of Directors of the Company in their Meeting held on January 29, 2018 along with the Limited Review Report issued by the Statutory Auditors of the Company.

We have also uploaded the financial results on the website of the Company, namely www.lauruslabs.com and also on the websites of BSE Ltd. and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com respectively.

This is for your information and records.

Thanking you,

Yours sincerely,
For Laurus Labs Limited


G. Venkateswar Reddy
Company Secretary



LAURUS LABS LIMITED

(CIN: L24239AP2005PLC047518)

Regd. Office: Plot No.21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India.

Corp. Office: 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad 500034, Telangana, India.

Tel: +91 40 3980 4333 ; Fax : +91 040 3980 4320 ; E-mail: secretarial@lauruslabs.com; Website: www.lauruslabs.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2017

₹ in Million

Sl. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31-Dec-17	30-Sep-17	31-Dec-16	31-Dec-17	31-Dec-16	31-Mar-17
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	(a) Revenue from operations (Refer note 7)	4,789.31	5,386.10	5,097.29	15,087.63	14,516.31	19,315.49
	(b) Other Income	99.44	66.26	129.66	241.12	232.37	334.38
	Total Income	4,888.75	5,452.36	5,226.95	15,328.75	14,748.68	19,649.87
2	Expenses						
	(a) Cost of materials consumed	2,655.52	3,098.76	2,735.08	8,055.25	7,975.48	10,187.05
	(b) Purchase of traded goods	75.25	77.98	26.05	201.04	101.36	129.60
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(273.24)	(363.28)	47.05	(528.40)	(315.00)	(349.00)
	(d) Excise duty (Refer note 7)	-	-	40.89	128.33	197.35	269.02
	(e) Employee benefits expense	647.25	633.72	549.04	1,908.16	1,615.67	2,233.90
	(f) Other expenses	811.05	813.17	705.76	2,358.89	2,015.77	2,768.57
	(g) Depreciation and amortisation expense	309.75	300.80	274.36	908.40	777.88	1,059.82
	(h) Finance costs	177.63	195.21	308.18	563.80	834.44	998.96
	Total expenses	4,403.21	4,756.36	4,686.41	13,595.47	13,202.95	17,297.92
3	Profit before tax (1-2)	485.54	696.00	540.54	1,733.28	1,545.73	2,351.95
4	Tax expense						
	(a) Current tax	110.88	144.99	115.52	393.52	346.78	533.09
	(b) Deferred tax	25.96	63.46	(20.80)	114.46	(1.03)	(94.45)
	Total Tax expense	136.84	208.45	94.72	507.98	345.75	438.64
5	Net Profit after tax before share of loss from associate (3-4)	348.70	487.55	445.82	1,225.30	1,199.98	1,913.31
6	Share of profit/(loss) from associate	-	-	4.37	-	(10.55)	(10.55)
7	Net Profit after taxes and share of loss from associate (5+6)	348.70	487.55	450.19	1,225.30	1,189.43	1,902.76
8	Other comprehensive income						
	(i) Items that will not reclassified to profit or loss in subsequent periods - Remeasurement of defined benefit plan	(4.21)	2.65	(2.88)	(6.07)	(7.91)	(10.55)
	(ii) Items that may be reclassified to profit or loss - Exchange differences in translating the financial statements of foreign operations	1.78	(0.83)	(0.34)	0.93	0.08	1.74
	(iii) Income tax relating to items that will not be reclassified to profit or loss in subsequent periods	1.45	(0.91)	0.99	2.10	2.74	3.62
	Total other comprehensive income	(0.98)	0.91	(2.23)	(3.04)	(5.09)	(5.19)
9	Total comprehensive income (7+8)	347.72	488.46	447.96	1,222.26	1,184.34	1,897.57
10	Paid-up equity share capital (face value ₹ 10/- each)	1,060.30	1,060.30	1,057.56	1,060.30	1,057.56	1,057.56
11	Other equity as per Balance Sheet of previous accounting year						12,246.92
12	Earnings per equity share (face value ₹ 10/- each)						
	- Basic (₹)	3.29	4.61	4.50	11.57	13.40	20.78
	- Diluted (₹)	3.28	4.58	4.48	11.53	11.95	18.79
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	

See accompanying notes to the financial results



Notes:

- The equity shares of the Company were listed on BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE') with effect from December 19, 2016.
- The above unaudited consolidated financial results as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on January 29, 2018. A limited review of the results for the quarter and nine months ended December 31, 2017 has been carried out by our statutory auditors. The statutory auditors of the Company have issued an unmodified opinion thereon.
 Further, the Company has availed the option to submit the unaudited consolidated financial results from the quarter ended June 30, 2017 onwards. The comparable figures of the unaudited consolidated financial results for the quarter and nine months ended December 31, 2016 have not been audited or reviewed by the statutory auditors. Management has exercised necessary due diligence to ensure that the unaudited consolidated financial results for the comparable periods provide a true and fair view of the Company's affairs.
- The unaudited consolidated financial results of the Company and its subsidiaries have been prepared in accordance with Ind AS 110, Consolidated Financial Statements, and the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting, notified under Section 133 of the Companies Act, 2013 ("the Act") read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016, to the extent notified and guidelines issued by the Securities and Exchange Board of India ("SEBI").

- The unaudited consolidated financial results include the results of the following subsidiaries:

Name of the Company	Country of Incorporation	Nature of relationship	% Holding
Laurus Synthesis Inc	USA	Subsidiary	100%
Sriam Labs Private Limited*	India	Subsidiary	100%

*Till October 31, 2016, the entity was an associate, with the Company having a share of 27%. With effect from November 01, 2016, the Company acquired the remaining 73% stake in the equity shares thereby making it a wholly owned subsidiary from that date. Hence the unaudited consolidated financial results for the quarter and nine months ended December 31, 2017 and quarter and nine months ended December 31, 2016 are not comparable.

- The Company incorporated wholly owned subsidiary, Laurus Holdings Limited in UK on July 10, 2017 and this subsidiary has not yet commenced any commercial operations.
 - The Company, through its wholly owned subsidiary, Laurus Holdings Limited, incorporated step down subsidiary, Laurus Generics Inc., USA on August 07, 2017.
 - The share capital in these subsidiaries is not yet infused. As these subsidiaries are yet to commence commercial operations, there are no financial transactions during the quarter and nine months ended December 31, 2017.
- The Company and its subsidiaries are engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per Ind AS 108 - 'Operating Segments'.
- The Government of India introduced the Goods and Services Tax (GST) with effect from July 01, 2017. Accordingly, in compliance with Indian Accounting Standard (Ind AS) 18 - 'Revenue', Revenue from operations for the quarter ended December 31, 2017 and September 30, 2017 are presented net of GST. Revenue from operations of earlier periods included Excise duty which is now subsumed in GST. Revenue from operations for the nine months ended December 31, 2017 includes Excise duty up to June 30, 2017.
- During the current quarter, the Company acquired the existing assets and liabilities of an API unit located at Visakhapatnam of Sriam Labs Private Limited, a wholly owned subsidiary of the Company, on a slump sale basis w.e.f. December 01, 2017. The Company accounted for the business combination in accordance with the requirement of Appendix C of Ind AS 103 Business Combination which lays down the principles in respect of accounting for business combinations of entities or businesses under common control. As required by the standard, pooling of interest method has been considered for common control business combination and accordingly, the assets and liabilities are reflected in the books of the Company at their respective carrying amounts. There is no impact of this transaction on the consolidated financial results.
- Corresponding previous period's figures have been regrouped/reclassified wherever necessary.

Place: Hyderabad
 Date : January 29, 2018

By order of the Board
 For Laurus Labs Limited



Dr. Satyanarayana Chava
 Whole Time Director & Chief Executive Officer



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
LAURUS LABS LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **LAURUS LABS LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the Quarter and Nine months ended December 31, 2017 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement, which is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. The Statement includes the results of the following subsidiaries:
 - a) Sriam Labs Private Limited, India
 - b) Laurus Synthesis Inc., United States of America
4. Based on our review conducted as stated above and based on the consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Q

5. We did not review the interim financial information of two subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of ₹ 154.54 million and ₹ 491.63 million for the Quarter and Nine months ended December 31, 2017 respectively, total loss after tax of ₹ 29.99 million and ₹ 108.96 million and total comprehensive loss of ₹ 29.99 million and ₹ 108.96 million for the Quarter and Nine months ended December 31, 2017 respectively, as considered in the unaudited consolidated financial results. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors.

Our report on the Statement is not modified in respect of these matters.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)


Ganesh Balakrishnan
Partner
(Membership No. 201193)

Place: Hyderabad
Date: January 29, 2018

LAURUS LABS LIMITED
 (CIN: L24239AP2005PLC047518)

Regd. Office: Plot No.21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam 531 021, Andhra Pradesh, India.

Corp. Office: 2nd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad 500034, Telangana, India.

Tel: +91 40 3980 4333 ; Fax : +91 040 3980 4320 ; E-mail: secretarial@lauruslabs.com; Website: www.lauruslabs.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2017

₹ in Million

Sl. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31-Dec-17 (Unaudited)	30-Sep-17 (Unaudited)	31-Dec-16 (Unaudited)	31-Dec-17 (Unaudited)	31-Dec-16 (Unaudited)	31-Mar-17 (Audited)
1	Income						
	(a) Revenue from operations (Refer note 5)	4,737.68	5,334.81	5,049.85	14,927.41	14,447.98	19,183.17
	(b) Other Income	98.04	65.88	127.59	238.30	230.14	319.44
	Total Income	4,835.72	5,400.69	5,177.44	15,165.71	14,678.12	19,502.61
2	Expenses						
	(a) Cost of materials consumed	2,649.65	3,096.80	2,730.16	8,037.23	7,960.60	10,156.83
	(b) Purchase of traded goods	75.24	77.99	26.05	201.04	101.36	129.60
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(277.37)	(362.84)	43.33	(520.43)	(318.72)	(360.79)
	(d) Excise duty (Refer note 5)	-	-	38.75	124.46	195.21	263.94
	(e) Employee benefits expense	600.79	586.67	482.41	1,751.22	1,424.36	1,957.94
	(f) Other expenses	823.21	817.56	748.23	2,390.78	2,123.34	2,897.41
	(g) Depreciation and amortisation expense	299.20	290.34	266.55	876.93	765.78	1,037.75
	(h) Finance costs	167.25	182.75	296.53	527.45	821.38	969.73
	Total expenses	4,337.97	4,689.27	4,632.01	13,388.68	13,073.31	17,052.41
3	Profit before tax (1-2)	497.75	711.42	545.43	1,777.03	1,604.81	2,450.20
4	Tax expense						
	(a) Current tax	110.88	144.99	115.52	393.52	346.78	533.09
	(b) Deferred tax	27.96	62.29	(34.22)	115.64	(14.45)	(82.48)
	Total Tax expense	138.84	207.28	81.30	509.16	332.33	450.61
5	Net Profit after tax (3-4)	358.91	504.14	464.13	1,267.87	1,272.48	1,999.59
6	Other comprehensive income						
	(i) Items that will not reclassified to profit or loss in subsequent periods - Remeasurement of defined benefit plan	(4.21)	2.65	(2.88)	(6.07)	(7.91)	(9.92)
	(ii) Income tax relating to items that will not reclassified to profit or loss in subsequent periods	1.45	(0.91)	0.99	2.10	2.74	3.43
	Total other comprehensive income	(2.76)	1.74	(1.89)	(3.97)	(5.17)	(6.49)
7	Total comprehensive income (5+6)	356.15	505.88	462.24	1,263.90	1,267.31	1,993.10
8	Paid-up equity share capital (face value ₹ 10/- each)	1,060.30	1,060.30	1,057.56	1,060.30	1,057.56	1,057.56
9	Other equity as per Balance Sheet of previous accounting year						12,524.27
10	Earnings per equity share (face value ₹ 10/- each)						
	- Basic (₹)	3.38	4.77	4.64	11.98	14.63	21.85
	- Diluted (₹)	3.37	4.74	4.62	11.93	12.78	19.74
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	

See accompanying notes to the financial results



Laurus Labs Limited**Corporate Office**

2nd Floor, Serene Chambers, Road No. 7
Banjara Hills, Hyderabad - 500034, Telangana, India
T +91 40 39804333 / 2342 0500 / 501
F +91 40 3980 4320

**LAURUS Labs**

Knowledge . Innovation . Excellence

Notes:

- The equity shares of the Company were listed on BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE') with effect from December 19, 2016.
- The above unaudited standalone financial results as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on January 29, 2018. A limited review of the results for the quarter and nine months ended December 31, 2017 has been carried out by our statutory auditors. The statutory auditors of the Company have issued an unmodified opinion thereon. The standalone financial results and other information for the quarter and nine months ended December 31, 2016 were reviewed by previous auditors - S R Batliboi & Associates LLP.
- These standalone financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting, notified under Section 133 of the Companies Act, 2013 ("the Act") read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016, to the extent notified and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- In accordance with Indian Accounting Standard (Ind AS) 108 on operating segments, segment information has been given in the consolidated financial results of the Company, and therefore no separate disclosure on segment information is given in these standalone financial results.
- The Government of India introduced the Goods and Services Tax (GST) with effect from July 01, 2017. Accordingly, in compliance with Indian Accounting Standard (Ind AS) 18 - 'Revenue', Revenue from operations for the quarter ended December 31, 2017 and September 30, 2017 are presented net of GST. Revenue from operations of earlier periods included Excise duty which is now subsumed in GST. Revenue from operations for the nine months ended December 31, 2017 includes Excise duty up to June 30, 2017.
- During the current quarter, the Company acquired the existing assets and liabilities of an API unit located at Visakhapatnam of Sriam Labs Private Limited, a wholly owned subsidiary of the Company, on a slump sale basis w.e.f. December 01, 2017. The Company accounted for the business combination in accordance with the requirement of Appendix C of Ind AS 103 Business Combination which lays down the principles in respect of accounting for business combinations of entities or businesses under common control. As required by the standard, pooling of interest method has been considered for common control business combination and accordingly, the assets and liabilities are reflected in the books of the Company at their respective carrying amounts. In accordance with the requirement of Appendix C of Ind AS 103 Business Combination, the financial information in the financial statements in respect of prior periods should be restated as if the business combination had occurred from the beginning of the preceding period in the financial statements, irrespective of the actual date of the combination. Accordingly the results have been restated from the date of business combination i.e. November 01, 2016 and consequently, the amounts for the quarter ended December 31, 2017, September 30, 2017, December 31, 2016 and nine months ended December 31, 2017, December 31, 2016 and year ended March 31, 2017 include the results of the aforementioned business acquired. The profit before tax as reported in published results for the prior periods are as below (without considering the impact of above restatement):

Particulars	Quarter ended		Nine months ended	Year ended
	30-Sep-17	31-Dec-16	31-Dec-16	31-Mar-17
Profit before tax	734.90	555.47	1,614.85	2,476.26

- Corresponding previous period's figures have been regrouped/reclassified wherever necessary.

By order of the Board
For Laurus Labs Limited

Dr. Satyanarayana Chava
Whole Time Director & Chief Executive Officer



Place: Hyderabad
Date : January 29, 2018



Registered Office : Plot No:21, Jawaharlal Nehru Pharma City, Parawada, Visakhapatnam - 531021, Andhra Pradesh, India. CIN : L24239AP2005PLC047518
T +91 891 3061222 F +91 891 3061270 E info@lauruslabs.com W lauruslabs.com

LAURUS Generics
Active Pharmaceutical Ingredients & Intermediates

LAURUS Ingredients
Specialty Ingredients for Nutraceutical & Allied Industry

LAURUS Synthesis
Contract Development & Manufacturing Services

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS


TO THE BOARD OF DIRECTORS OF LAURUS LABS LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **LAURUS LABS LIMITED** ("the Company"), for the Quarter and Nine months ended December 31, 2017 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)


Ganesh Balakrishnan
Partner
(Membership No. 201193)

Place: Hyderabad
Date: January 29, 2018